
% REDUCTION IN ANTI-PN RESPONSE
100
90
80
70
60
50
40
30
20
10
0
4.5
1.5
0.5
0.167
0.56
0.018
0.006
TOLEROGEN: nMOLES/MOUSE

FIG. 1


ANTI-KLH % OF STANDARD POOL
MEAN AND S.D.
300
200
100
0
NONE
4.5
1.5
0.5
0.167
0.056
0.018
0.006
TOLEROGEN: nMOLES/MOUSE

FIG. 2


100
90
80
70
60
50
40
30
20
10
0
% REDUCTION IN ANTI-PN RESPONSE
.1
1
10
TOLEROGEN: nMOLES/MOUSE
20 MER (11-II)
16 MER (11-IV)
24 MER (11-VI)
32 MER (11-VIII)

FIG. 3


% REDUCTION IN ANTI-PN RESPONSE
100
90
80
70
60
50
40
30
20
10
0
HAD-AHAB-TEG
20-mer
MIX
4.5
1.125
0.28
0.07
0.0175
0.0044
0.0011
0.0003
CONJUGATE 20-II
TOLEROGEN: nMOLES/MOUSE

FIG. 4


% REDUCTION IN ANTI-PN RESPONSE
110
100
90
80
70
60
50
40
30
20
10
0
4.5
1.5
0.5
.0167
0.056
0.018
0.006
TOLEROGEN: nMOLES/MOUSE

FIG. 5



DABA—PEG

3-I, **PN** = $(CA)_{10}$

3-II, **PN** = $(CA)_{10}.(TG)_{10}$



$BAHA_{OX}$—EDDA

11-I, PN = $(CA)_{10}$

11-II, PN = $(CA)_{10}.(TG)_{10}$

11-IV, PN = $(CA)_8.(TG)_8$

11-VI, PN = $(CA)_{12}.(TG)_{12}$

11-VIII, PN = $(CA)_{16}.(TG)_{16}$

FIG. 6A



BAHA—EDDA

17-I **PN** = $(CA)_{10}$

17-II **PN**= $(CA)_{10}$.$(TG)_{10}$



AHAB−TEG

20-I **PN** = $(CA)_{10}$

20-II **PN** = $(CA)_{10}$.$(TG)_{10}$

FIG. 6B



AHAB−TEG (phosphorothioate)

20-III **PN** = $(CA)_{10}$

20-IV **PN** = $(CA)_{10}.(TG)_{10}$

FIG. 6C


HO(CH2)6SCH2COHN(CH2)5CONH
HO(CH2)6SCH2COHN(CH2)5CONH
N
O
O(CH2CH2O)2CH2CH2O
O
N
NHCO(CH2)5NHCOCH2S(CH2)6OH
NHCO(CH2)5NHCOCH2S(CH2)6OH
HAD—AHAB—TEG

FIG. 7


INCORPORATION OF ^{3}H THYMIDINE (CPM)
2000
1000
0
CONTROL
1
2
3
4
5
PEPTIDE

FIG. 8


0.5
0.4
0.3
0.2
0.1
O.D. 450 nm
FORM BUFFER
CONJUGATE 2
10-3
10-2
10-1
SERUM DILUTION

FIG. 9


1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
O.D. 450 nm
FORM BUFFER
CONJUGATE 2
10^{-3}
10^{-2}
10^{-1}
SERUM DILUTION

FIG. 10


150
100
50
0
RELATIVE NUMBER OF ANTIBODY FORMING CELLS
FORMULATION BUFFER (CONTROL)
CONJUGATE 2
TREATMENT

FIG. 11


0.4
0.3
0.2
0.1
0.0
O.D. 450 nm
FORM BUFFER
CONJUGATE 4
10^{-3}
10^{-2}
10^{-1}
SERUM DILUTION

FIG. 12



MELITTIN CONJUGATE #1, R = H_2N–Cys–Trp–Ile–Lys–Arg–Lys–Arg–Gln–Gln–Gly–CO_2H

AVERAGE n = APPROX. 74



MELITTIN CONJUGATE #2, R = H_2N–Cys–Trp–Ile–Lys–Arg–Lys–Arg–Gln–Gln–Gly–CO_2H

MELITTIN CONJUGATE #3, R = H_2N–Trp–Ile–Lys–Arg–Lys–Arg–Gln–Gln–Lys–Cys–Gly–CO_2H

MELITTIN CONJUGATE #4, R = H_2N–Cys–Ile–Ser–Trp–Ile–Lys–Arg–Lys–Arg–Gln–Gln–Gly–CO_2H

MELITTIN CONJUGATE #5, R = (H_2N–Trp–Ile–Lys–Arg–Lys–Arg–Gln–Gln)$_2$–Lys–Cys–Gly–CO_2H

MELITTIN PEPTIDES ATTACHED THROUGH SULFUR ATOM ON ADDED CYSTEINE,
AVERAGE N = APPROX. 74

FIG. 13


100
80
60
40
20
0
PERCENT REDUCTION IN ANTI-dsPN
0.1
1
10
100
1000
DOSE (ug)
LJP-249 A
LJP-249 B
LJP-105

FIG. 14


ANTI DNA TITER (OD490 nm)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
40
60
80
100
120
140
160
DAYS
CONTROL
300 µg/TWICE PER WEEK

FIG. 15